

PharmLabs San Diego Certificate of Analysis



Sample FVKD x Loud-2.5g-aio-thca-Coastal Kush

Delta9 THC UI	THCa 65.14%	Total THC (THCa * 0.877 + THC) 57.13%	Delta8 THC 13.45%
---------------	-------------	---------------------------------------	-------------------

Sample ID SD260514-008 (138145)	Matrix Concentrate	Batch ID DSP0625-001
Tested for FVKD x Loud 1740 h dell range blvd #281 Cheyenne, WY 82009		
Received May 14, 2026	Reported May 19, 2026	
Analyses executed CANX, PRY		Unit Mass (g) 2.5

Laboratory note: The Δ9-THC results in this particular sample is inconclusive due to potential interferences from several cannabinoids when analyzed using our GC MS/MS D9C method. As a result, this sample will not undergo testing via the GC MS/MS D9C method. However, there are currently no interferences detected with any other cannabinoids in this sample when employing HPLC.COA Update: 05/19/26 -"Tested for" and Batch info corrected as per client request.

CANx - Cannabinoids

Analyzed May 14, 2026 | Instrument HPLC-VWD | Method SOP-001
 The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabinarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND
(+/-)-9B-Hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	0.09	0.91	2.28
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND
Tetrahydrocannabinarin (THCV)	0.049	0.162	ND	ND	ND
Δ8-tetrahydrocannabinarin (Δ8-THCV)	0.021	0.064	ND	ND	ND
Cannabidihexol (CBDH)	0.014	0.042	ND	ND	ND
Tetrahydrocannabinol (Δ9-THCB)	0.01	0.029	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	0.48	4.81	12.02
Cannabidiphoral (CBDP)	0.016	0.049	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	UI	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	13.45	134.52	336.30
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	65.14	651.45	1628.62
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.02	0.061	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCA)	0.063	0.065	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCA)	0.191	0.196	ND	ND	ND
Δ9-Tetrahydrocannabinophoral (Δ9-THCP)	0.017	0.8	ND	ND	ND
Δ8-Tetrahydrocannabinophoral (Δ8-THCP)	0.041	0.8	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			57.13	571.32	1428.30
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			70.58	705.84	1764.60
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND
Total CBG (CBGA * 0.877 + CBG)			0.08	0.80	2.00
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND
Total Cannabinoids Analyzed			71.14	711.45	1778.62

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: RP0611043
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Tue, 19 May 2026 16:00:55 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.